Navigation Links
Telik Announces Third Quarter 2011 Financial Results
Date:11/3/2011

PALO ALTO, Calif., Nov. 3, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today reported a net loss of $2.8 million, or $0.05 per share, for the third quarter ended September 30, 2011, compared with a net loss of $4.7 million, or $0.09 per share, for the comparable period in 2010.

For the quarter ended September 30, 2011, total operating costs and expenses were $2.9 million, compared with $4.7 million in the third quarter of 2010.  Operating expenses in the 2011 third quarter included stock-based compensation expense of approximately $0.5 million.  Operating expenses were approximately 39% lower in the third quarter of 2011 compared with the same period in 2010, primarily due to lower headcount, clinical development and facility expenses.

For the nine months ended September 30, 2011, Telik reported a net loss of $9.5 million, or $0.18 per share, compared with a net loss of $14.9 million, or $0.28 per share, for the same period in 2010.  Total operating expenses for the first nine months of 2011 were $9.6 million, compared with $15.1 million for the same period in 2010.  Operating expenses in the first nine months of 2011 included approximately $1.2 million in stock-based compensation expense.  The reduction in operating expenses of approximately 37% in the first nine months of 2011 compared with the same period in 2010 was primarily due to lower headcount, reduced clinical trial expenses, lower stock-based compensation and lower facility costs.

At September 30, 2011, Telik had $14.0 million in cash, cash equivalents and investments including restricted investments, compared to $24.1 million at December 31, 2010.

About Telik

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer.  The company's most advanced drug candidate is Telintra®, a modified glutathione analog intended for the treatment of hematologic malignancies including myelodysplastic syndrome; followed by Telcyta®, a cancer activated prodrug for the treatment of a variety of cancers. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.

Telik, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.Telik, Inc.Statements of Operations(In thousands, except per share amounts)(Unaudited)Three Months Ended Nine Months EndedSeptember 30,September 30,2011201020112010Operating costs and expenses:Research and development

$
,305$
2,569$  4,464$
8,202General and administrative

1,5502,1015,0906,856Total operating costs and expenses

2,8554,6709,55415,058Loss from operations

(2,855)(4,670)(9,554)(15,058)Interest and other income (expense), net

71731132Net loss

$
(2,848)$
(4,653)$ (9,523)$ (14,926)Basic and diluted net loss per share

$
(0.05)$
(0.09)$   (0.18)$
(0.28)Weighted average shares used to calculate basic and diluted net loss per share

53,96253,55353,87053,514Selected Balance Sheet Data(In thousands)(Unaudited)September 30,December 31,20112010Cash, cash equivalents, investments and restricted investments

$
4,033$
24,064Total assets

14,93625,029Stockholders' equity

10,27318,369
'/>"/>

SOURCE Telik, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Telik Announces Publication of a Report of Complete Response of G-CSF Resistent Severe Idiopathic Chronic Neutropenia Following Treatment with Telintra®
2. Telik Announces Ezatiostat (Telintra®) Preclinical Presentation at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Telik Announces Initiation of a Phase 2b Clinical Trial of Telintra® (Ezatiostat HCL) in Patients With Low to Intermediate-1 Risk Non-Deletion (5q) Myelodysplastic Syndrome
4. Telik Announces Publication in the Journal Cancer of a Phase 2 Randomized Multicenter Study of Two Extended Dosing Schedules of Oral Ezatiostat in Low to Intermediate-1 Risk Myelodysplastic Syndrome
5. Telik Announces First Quarter 2011 Financial Results
6. Telik Announces Presentation of New Data on the Characterization of Novel Ezatiostat (TELINTRA®, TLK199) Analogs at American Association for Cancer Research Annual Meeting
7. Telik Announces Presentation and Webcast at 10th Annual Needham Healthcare Conference
8. Telik Announces Fourth Quarter and 2010 Year End Financial Results and 2011 Financial Guidance
9. Telik Announces Presentation and Webcast at 13th Annual BIO CEO & Investor Conference
10. Telik Announces Presentation at American Society of Hematology Annual Meeting
11. Telik Announces Third Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... Zealand , May 24, 2016 ... informatics solutions for the healthcare sector, has been named the ... Zealand Hi-Tech Awards 2016. Dr Bruce Davey ... acknowledgement for our team.  It,s really good to be recognised ... healthcare internationally. Our products are used in 35 countries around ...
(Date:5/24/2016)... May 24, 2016 Los ... terapia del mundo, introduce catéteres para la intervención ... OrbusNeich, una compañía global especializada en el suministro ... expandido su cartera incluyendo productos para tratar la ... Scoreflex™ PTA son los dispositivos de primera entrada ...
(Date:5/23/2016)... , May 23, 2016 ... Handling Equipment Market by Product (Wheelchair, Scooters, Medical ... (Bariatric Care, Critical Care, Wound), Accessories (Lifting, Transfer) ... to 2021", published by MarketsandMarkets, the patient handling ... Billion by 2021 at a CAGR of 10.5% ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... May 25, 2016 , ... ... “Advancing Drug Development through Molecular Imaging.” The focus of ADDMI-IG will be geared ... discovery and development pipeline issues. Through ADDMI-IG WMIS will provide a platform for ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... supporting the real time adjudication of medical service claims by Pharmacy Benefit Managers ... current medical claims management software. The TransactRx Cross Benefit Clearinghouse receives standard professional ...
(Date:5/25/2016)... ... ... than fifty years, we've suffered whiplash as each new scientific study seemed to contradict the ... advice – advice that was supposed to keep us healthy and slim. And what happened? ... considered to be overweight and more than 1 in 3 adults are considered to be ...
(Date:5/25/2016)... ... ... Consumer access to organic foods and grower access to food processers is about ... and other plant-based foods, will introduce the first consumer product (a new breakfast cereal) ... Organic Products. , The transitional designation means the cereal was made using at least ...
(Date:5/24/2016)... ... May 24, 2016 , ... According to an article ... people randomly assigned to reduce the amount of calories they consumed by 25% experienced ... body weight enjoyed better sleep, improved quality of life, and enhanced sexual function compared ...
Breaking Medicine News(10 mins):